1-[3-(2-phenylethyl)benzo[b]thiophen-5-yl]-1-deoxy-6-O-ethoxycarbonyl-β-D-glucopyranose | 864535-72-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[3-(2-phenylethyl)benzo[b]thiophen-5-yl]-1-deoxy-6-O-ethoxycarbonyl-β-D-glucopyranose
• 英文别名: 1-[3-(2-Phenylethyl)benzo[b]thiophen-5-yl]-1-deoxy-6-O-ethoxycarbonyl-beta-D-glucopyranose；ethyl [(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-[3-(2-phenylethyl)-1-benzothiophen-5-yl]oxan-2-yl]methyl carbonate
• CAS: 864535-72-8
• 化学式: C₂₅H₂₈O₇S
• 分子量: 472.559
• InChiKey: DYEVHARHNYRGAA-ZXGKGEBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  134
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  1-[3-(2-Phenylethyl)benzo[b]thiophen-5-yl]-1-deoxy-β-D-glucopyranose 、 氯甲酸乙酯 在 2,4,6-三甲基吡啶 作用下， 反应 7.0h， 生成 1-[3-(2-phenylethyl)benzo[b]thiophen-5-yl]-1-deoxy-6-O-ethoxycarbonyl-β-D-glucopyranose
  参考文献：
  名称：

  EP1721904

  摘要：

  公开号：

文献信息

• Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
  申请人：Fushimi Nobuhiko

  公开号：US20070197450A1

  公开（公告）日：2007-08-23

  The present invention provides fused heterocyclic derivatives represented by the following general formula (I) or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, in the formula R 1 to R 4 represent H, OH, an amino group, etc.; R 5 and R 6 represent H, OH, a halogen atom, an option ally substituted alkyl group, etc.; Q represents alkylene, alkenylene, etc.; ring A represents an aryl group or a heteroaryl group; the following ring (R1) represents a group represented by the following ring (R2); G represents a group represented by the following general formula (G-1) or (G-2) (E 1 represents H, F or OH; and E represents H, F, a methyl group, etc.), and pharmaceutical compositions comprising the same, and pharmaceutical uses thereof.

  本发明提供了下列通式（I）表示的融合杂环衍生物，或其药学上可接受的盐或前药，它们在人体SGLT中表现出抑制活性，并可用作预防或治疗与高血糖相关的疾病，如糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症或肥胖症的药物。在该通式中，R1至R4表示H、OH、氨基等；R5和R6表示H、OH、卤原子、可选取代的烷基等；Q表示烷基、烯基等；环A表示芳基或杂芳基；下列环（R1）表示下列环（R2）所表示的基团；G表示下列通式（G-1）或（G-2）所表示的基团（E1表示H、F或OH；E表示H、F、甲基基团等），以及包含它们的药物组成物和药物用途。
• FUSED HETEROCYCLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1721904A1

  公开（公告）日：2006-11-15

  The present invention provides fused heterocyclic derivatives represented by the following general formula (I) or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, in the formula R1 to R4 represent H, OH, an amino group, etc.; R5 and R6 represent H, OH, a halogen atom, an optionally substituted alkyl group, etc. ; Q represents alkylene, alkenylene, etc.; ring A represents an aryl group or a heteroaryl group; the following ring (R1) represents a group represented by the following ring (R2); G represents a group represented by the following general formula (G-1) or (G-2) (E1 represents H, F or OH; and E2 represents H, F, a methyl group, etc.), and pharmaceutical compositions comprising the same, and pharmaceutical uses thereof.

  本发明提供了由下通式(I)代表的融合杂环衍生物或其药学上可接受的盐或其原药，它们在人SGLT中表现出抑制活性，可用作预防或治疗与高血糖相关的疾病如糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症或肥胖症的药物，式中R1至R4代表H、OH、氨基等；R5和R6代表H、OH、卤原子、任选取代的烷基等；Q代表亚烷基、烯基等；环A代表芳基或杂环。R5和R6代表H、OH、卤原子、任选取代的烷基等；Q代表亚烷基、烯基等；环A代表芳基或杂芳基；下环（R1）代表下环（R2）所代表的基团；G代表下通式（G-1）或（G-2）所代表的基团（E1代表H、F或OH；E2代表H、F、甲基等），以及由其组成的药物组合物及其药物用途。
• US8058245B2
  申请人：——

  公开号：US8058245B2

  公开（公告）日：2011-11-15
• EP1721904
  申请人：——

  公开号：——

  公开（公告）日：——